Savings, Cimzia sales push UCB first-half core profit above forecasts

July 28, 2016 5:47 AM

22 0

BRUSSELS Belgian pharmaceutical group UCB on Thursday reported a better-than-expected core profit in the first half of 2016, as it reduced operating expenses and its inflammatory disease drug Cimzia performed well.

Core profit rose 18 percent in the first half to 549 million euros ($607.5 million), above the 518 million euros expected in a Reuters poll.

Read more

To category page